Cleveland BioLabs

Cleveland BioLabs, Inc. (NASDAQ: CBLI) is a clinical-stage biotechnology company with a focus on oncology development. It specializes in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. The company was founded in 2003 and is headquartered in Buffalo, New York. It has license agreements and collaborations with the Cleveland Clinic, Roswell Park Comprehensive Cancer Center, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute.
Since 2012, Yakov Cogan has been the CEO of Cleveland BioLabs.
History.
Cleveland BioLabs was founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007.
In 2018, the company entered into a joint venture with Buffalo-based Everon Biosciences. The joint venture, Genome Protection Inc., will develop pharmaceuticals that have anti-aging applications, using Cleveland Biolabs' acute radiation exposure drug, Entolimod.
Genome Protection Inc. subsequently received a $10.5 million (US) investment from Israeli businessman and owner of the Premier League’s Chelsea FC, Roman Abramovich.
Financials.
The following table shows key financial figures for the company for 2011, 2012 and 2013 (parenthesis represent negative figures).
Subsidiaries.
Cleveland Biolabs has two majority-owned subsidiaries: